LLY Jun 2024 880.000 call
| Previous close | 14.75 |
| Open | 12.47 |
| Bid | 12.00 |
| Ask | 12.60 |
| Strike | 880.00 |
| Expiry date | 2024-06-21 |
| Day's range | 10.49 - 15.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.03k |
- Yahoo Finance Video
Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter joins Catalysts to discuss the state of the weight-loss market and the potential headwinds for these pharmaceutical companies. "There's been a duopoly situation via Lilly and Novo," Richter explains. She points to Zealand (ZEAL.CO), Amgen (AMGN), and Regeneron (REGN) as companies she's watching that could become competitors in the weight-loss market. She notes that Eli Lilly and Novo Nordisk are facing limited supply as demand skyrockets. The two pharmaceutical companies have to make significant investments to expand manufacturing capabilities, and Richter explains, "I think what everybody realizes is based on the opportunity, the investment in manufacturing and supply has to come in much earlier than perhaps thought before." For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Investor's Business DailyGilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.
ZacksPharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
